Caio Bezerra Machado

Mr. Caio Bezerra Machado


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAna Beatriz Aguiar Sanford
Ana Beatriz Aguiar Sanford
LCLeidivan Sousa da Cunha
Leidivan Sousa da Cunha
CMCaio Bezerra Machado
Caio Bezerra Machado
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
ASAbigail Nayara dos Santos Silva
Abigail Nayara dos Santos Silva
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
The circadian clock (CC) is a daily system that regulates the oscillations of physiological processes and can respond to the external environment in order to maintain internal homeostasis. For the functioning of the CC, the clock genes (CG) act in different metabolic pathways through the clock-controlled genes (CCG), providing cellular regulation. The CC’s interruption can result in the development of different diseases, such as neurodegenerative and metabolic disorders, as well as cancer. Leukemias correspond to a group of malignancies of the blood and bone marrow that occur when alterations in normal cellular regulatory processes cause the uncontrolled proliferation of hematopoietic stem cells. This review aimed to associate a deregulated CC with the manifestation of leukemia, looking for possible pathways involving CG and their possible role as leukemic biomarkers.

5 April 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
CMCaio Bezerra Machado
Caio Bezerra Machado
IBIgor Valentim Barreto
Igor Valentim Barreto
GSGiulia Freire Sampaio
Giulia Freire Sampaio
DODeivide de Sousa Oliveira
Deivide de Sousa Oliveira
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
Acute myeloid leukemia (AML) is a hematologic malignancy that occurs due to alterations such as genetic mutations, chromosomal translocations, or changes in molecular levels. These alterations can accumulate in stem cells and hematopoietic progenitors, leading to the development of AML, which has a prevalence of 80% of acute leukemias in the adult population. Recurrent cytogenetic abnormalities, in addition to mediating leukemogenesis onset, participate in its evolution and can be used as established diagnostic and prognostic markers. Most of these mutations confer resistance to the traditionally used treatments and, therefore, the aberrant protein products are also considered therapeutic targets. The surface antigens of a cell are characterized through immunophenotyping, which has the ability to identify and differentiate the degrees of maturation and the lineage of the target cell, whether benign or malignant. With this, we seek to establish a relationship according to the molecular aberrations and immunophenotypic alterations that cells with AML present.

24 June 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
IBIgor Valentim Barreto
Igor Valentim Barreto
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
CMCaio Bezerra Machado
Caio Bezerra Machado
LPLaudreísa da Costa Pantoja
Laudreísa da Costa Pantoja
RRRodrigo Monteiro Ribeiro
Rodrigo Monteiro Ribeiro
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
Hematopoietic stem cells (HSCs) are known for their ability to proliferate and self-renew, thus being responsible for sustaining the hematopoietic system and residing in the bone marrow (BM). Leukemic stem cells (LSCs) are recognized by their stemness features such as drug resistance, self-renewal, and undifferentiated state. LSCs are also present in BM, being found in only 0.1%, approximately. This makes their identification and even their differentiation difficult since, despite the mutations, they are cells that still have many similarities with HSCs. Although the common characteristics, LSCs are heterogeneous cells and have different phenotypic characteristics, genetic mutations, and metabolic alterations. This whole set of alterations enables the cell to initiate the process of carcinogenesis, in addition to conferring drug resistance and providing relapses. The study of LSCs has been evolving and its application can help patients, where through its count as a biomarker, it can indicate a prognostic factor and reveal treatment results. The selection of a target to LSC therapy is fundamental. Ideally, the target chosen should be highly expressed by LSCs, highly selective, absence of expression on other cells, in particular HSC, and preferentially expressed by high numbers of patients. In view of the large number of similarities between LSCs and HSCs, it is not surprising that current treatment approaches are limited. In this mini review we seek to describe the immunophenotypic characteristics and mechanisms of resistance presented by LSCs, also approaching possible alternatives for the treatment of patients.

Verified
Journal Article
Open access
PDF file
CMCaio Bezerra Machado
Caio Bezerra Machado
LCLeidivan Sousa da Cunha
Leidivan Sousa da Cunha
JMJersey Heitor Maués
Jersey Heitor Maués
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
MOMarcelo Braga de Oliveira
Marcelo Braga de Oliveira
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
Human T cell leukemia virus type 1 (HTLV-1) was identified as the first pathogenic human retrovirus and is estimated to infect 5 to 10 million individuals worldwide. Unlike other retroviruses, there is no effective therapy to prevent the onset of the most alarming diseases caused by HTLV-1, and the more severe cases manifest as the malignant phenotype of adult T cell leukemia (ATL). MicroRNA (miRNA) dysfunction is a common feature of leukemogenesis, and it is no different in ATL cases. Therefore, we sought to analyze studies that reported deregulated miRNA expression in HTLV-1 infected cells and patients’ samples to understand how this deregulation could induce malignancy. Through in silico analysis, we identified 12 miRNAs that stood out in the prediction of targets, and we performed functional annotation of the genes linked to these 12 miRNAs that appeared to have a major biological interaction. A total of 90 genes were enriched in 14 KEGG pathways with significant values, including TP53, WNT, MAPK, TGF-β, and Ras signaling pathways. These miRNAs and gene interactions are discussed in further detail for elucidation of how they may act as probable drivers for ATL onset, and while our data provide solid starting points for comprehension of miRNAs’ roles in HTLV-1 infection, continuous effort in oncologic research is still needed to improve our understanding of HTLV-1 induced leukemia.

Verified
Journal Article
Open access
PDF file
RGRenan Brito Gadelha
Renan Brito Gadelha
CMCaio Bezerra Machado
Caio Bezerra Machado
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
LPLaudreísa da Costa Pantoja
Laudreísa da Costa Pantoja
IBIgor Valentim Barreto
Igor Valentim Barreto
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
The WD repeat containing antisense to TP53 (WRAP53) gene codifies an antisense transcript for tumor protein p53 (TP53), stabilization (WRAP53α), and a functional protein (WRAP53β, WDR79, or TCAB1). The WRAP53β protein functions as a scaffolding protein that is important for telomerase localization, telomere assembly, Cajal body integrity, and DNA double-strand break repair. WRAP53β is one of many proteins known for containing WD40 domains, which are responsible for mediating a variety of cell interactions. Currently, WRAP53 overexpression is considered a biomarker for a diverse subset of cancer types, and in this study, we describe what is known about WRAP53β’s multiple interactions in cell protein trafficking, Cajal body formation, and DNA double-strand break repair and its current perspectives as a biomarker for cancer.

25 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
IBIgor Valentim Barreto
Igor Valentim Barreto
CMCaio Bezerra Machado
Caio Bezerra Machado
Davi Benevides AlmeidaDavi Benevides Almeida
Davi Benevides Almeida
FPFlávia Melo Cunha de Pinho Pessoa
Flávia Melo Cunha de Pinho Pessoa
RGRenan Brito Gadelha
Renan Brito Gadelha
Caroline Aquino Moreira-NunesCaroline Aquino Moreira-Nunes
Caroline Aquino Moreira-Nunes
Multiple myeloma (MM) is a blood cell neoplasm characterized by excessive production of malignant monoclonal plasma cells (activated B lymphocytes) by the bone marrow, which end up synthesizing antibodies or antibody fragments, called M proteins, in excess. The accumulation of this production, both cells themselves and of the immunoglobulins, causes a series of problems for the patient, of a systemic and local nature, such as blood hyperviscosity, renal failure, anemia, bone lesions, and infections due to compromised immunity. MM is the third most common hematological neoplasm, constituting 1% of all cancer cases, and is a disease that is difficult to treat, still being considered an incurable disease. The treatments currently available cannot cure the patient, but only extend their lifespan, and the main and most effective alternative is autologous hematopoietic stem cell transplantation, but not every patient is eligible, often due to age and pre-existing comorbidities. In this context, the search for new therapies that can bring better results to patients is of utmost importance. Protein tyrosine kinases (PTKs) are involved in several biological processes, such as cell growth regulation and proliferation, thus, mutations that affect their functionality can have a great impact on crucial molecular pathways in the cells, leading to tumorigenesis. In the past couple of decades, the use of small-molecule inhibitors, which include tyrosine kinase inhibitors (TKIs), has been a hallmark in the treatment of hematological malignancies, and MM patients may also benefit from TKI-based treatment strategies. In this review, we seek to understand the applicability of TKIs used in MM clinical trials in the last 10 years.